1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

09 Dec 2020
Admin
News Article

Zydus Cadila Gets Permission From Dcgi For Phase-1 Clinical Trial Of Novel Molecule Zyil1

Drug Firm Zydus Cadila On Monday Said It Has Received Permission From Drugs Controller General Of India (Dcgi) To Initiate Phase-1 Clinical Trial Of Its Novel Molecule Zyil1, Indicated For Use As An Inhibitor For Inflammation Condition 'Nlrp3'. In A Regulatory Filing, Zydus Cadila Said "It Has Received Permission To Initiate The Phase 1 Clinical Trial Of Zyil1, A Novel Oral Small Molecule Nlrp3 Inhibitor Candidate. Nlrp3 Inflammasomes Are Involved In The Inflammation Process".This Harmful Inflammation Within The Body Leads To The Onset And Development Of Various Kinds Of Diseases, Including Acute Respiratory Distress Syndrome (Ards), Auto-Immune Diseases, Inflammatory Diseases, Cardiovascular Diseases, Metabolic Disorders, Gastro-Intestinal Diseases (Inflammatory Bowel Disease), Renal Diseases And Cns Diseases, The Company Added.Pankaj R Patel, Chairman, Cadila Healthcare Said: "We Will Study The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Zyil1 In This Phase I Clinical Trial In Healthy Human Volunteers. We Are Committed To Developing These Pioneering Novel Treatments To The Clinic For The Patients In Need." Last Month, Zydus Cadila Had Filed The Investigational New Drug Application For Zyil1, Positioned For Management Of Critically Ill Covid-19 Patients. Shares Of Cadila Healthcare Were Trading 1.85 Per Cent Higher At Rs 479.70 Apiece On Bse.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!